Voyager Therapeutics, Inc. (VYGR) stock
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3040% below fair value
$1.73+0.03 (+1.76%)
Close on Nov 13, 2026Market cap $106.60MP/E –Yield –
Voyager Therapeutics cash
Cash and short-term investments held at the end of each period.
Voyager Therapeutics's cash was $132.10M at Sep 30, 2026. For fiscal 2025 it was $201.70M, down 39.3% from the year before. Over ten years it grew 0.4% a year on average. The highest annual figure on record is $332.40M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $201.70M | -39.3% |
| FY2024 | Dec 31, 2024 | $332.40M | +44.0% |
| FY2023 | Dec 31, 2023 | $230.90M | +94.4% |
| FY2022 | Dec 31, 2022 | $118.80M | -11.6% |
| FY2021 | Dec 31, 2021 | $134.32M | -26.6% |
| FY2020 | Dec 31, 2020 | $182.92M | -35.2% |
| FY2019 | Dec 31, 2019 | $282.27M | +80.3% |
| FY2018 | Dec 31, 2018 | $156.54M | -7.8% |
| FY2017 | Dec 31, 2017 | $169.79M | -3.1% |
| FY2016 | Dec 31, 2016 | $175.15M | -10.0% |
| FY2015 | Dec 31, 2015 | $194.65M | +2666.9% |
| FY2014 | Dec 31, 2014 | $7.04M | +5111.1% |
| FY2013 | Dec 31, 2013 | $135.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $132.10M | -42.3% |
| Q2 FY2026 | Jun 30, 2026 | $148.80M | -43.2% |
| Q1 FY2026 | Mar 31, 2026 | $171.70M | -41.8% |
| Q4 FY2025 | Dec 31, 2025 | $201.70M | -39.3% |
| Q3 FY2025 | Sep 30, 2025 | $229.00M | -33.7% |
| Q2 FY2025 | Jun 30, 2025 | $262.00M | -29.4% |
| Q1 FY2025 | Mar 31, 2025 | $295.10M | -26.3% |
| Q4 FY2024 | Dec 31, 2024 | $332.40M | +44.0% |
| Q3 FY2024 | Sep 30, 2024 | $345.40M | +36.6% |
| Q2 FY2024 | Jun 30, 2024 | $371.00M | +36.0% |
| Q1 FY2024 | Mar 31, 2024 | $400.50M | +46.5% |
| Q4 FY2023 | Dec 31, 2023 | $230.90M | +94.4% |
| Q3 FY2023 | Sep 30, 2023 | $252.90M | +92.2% |
| Q2 FY2023 | Jun 30, 2023 | $272.70M | +84.1% |
| Q1 FY2023 | Mar 31, 2023 | $273.30M | +63.8% |
| Q4 FY2022 | Dec 31, 2022 | $118.80M | -11.6% |
| Q3 FY2022 | Sep 30, 2022 | $131.60M | +8.3% |
| Q2 FY2022 | Jun 30, 2022 | $148.10M | +3.6% |
| Q1 FY2022 | Mar 31, 2022 | $166.80M | +8.9% |
| Q4 FY2021 | Dec 31, 2021 | $134.32M | -26.6% |
| Q3 FY2021 | Sep 30, 2021 | $121.50M | -39.2% |
| Q2 FY2021 | Jun 30, 2021 | $143.00M | -37.7% |
| Q1 FY2021 | Mar 31, 2021 | $153.10M | -39.0% |
| Q4 FY2020 | Dec 31, 2020 | $182.92M | -35.2% |
| Q3 FY2020 | Sep 30, 2020 | $200.00M | -34.9% |
| Q2 FY2020 | Jun 30, 2020 | $229.70M | -29.9% |
| Q1 FY2020 | Mar 31, 2020 | $250.90M | -30.0% |
| Q4 FY2019 | Dec 31, 2019 | $282.27M | +80.3% |
| Q3 FY2019 | Sep 30, 2019 | $307.40M | +71.2% |
| Q2 FY2019 | Jun 30, 2019 | $327.50M | +66.2% |
| Q1 FY2019 | Mar 31, 2019 | $358.50M | +64.3% |
| Q4 FY2018 | Dec 31, 2018 | $156.54M | -7.8% |
| Q3 FY2018 | Sep 30, 2018 | $179.60M | +43.0% |
| Q2 FY2018 | Jun 30, 2018 | $197.00M | +39.4% |
| Q1 FY2018 | Mar 31, 2018 | $218.20M | +38.4% |
| Q4 FY2017 | Dec 31, 2017 | $169.79M | -3.1% |
| Q3 FY2017 | Sep 30, 2017 | $125.60M | – |
| Q2 FY2017 | Jun 30, 2017 | $141.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $157.70M | – |
| Q4 FY2016 | Dec 31, 2016 | $175.15M | – |
See a number that looks wrong?